Skip to content

Research progress of botulinum toxin in the treatment of rosacea associated erythema and flushing

Research progress of botulinum toxin in the treatment of rosacea associated erythema and flushing

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100052705
Enrollment
Unknown
Registered
2021-11-03
Start date
2021-01-01
Completion date
Unknown
Last updated
2022-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rosacea

Interventions

experimental side:Botox injection
control side:normal saline

Sponsors

Chengdu Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 39 Years

Inclusion criteria

Inclusion criteria: It is in line with the diagnosis of rosacea, with erythema and flushing as the main symptoms, and the skin lesions on both sides are uniform (Fitzpatrick III-IV skin).

Exclusion criteria

Exclusion criteria: 1.Pregnant, breastfeeding women and women who need childbirth within six months; 2.Combined with other skin diseases and systemic diseases; 3.Contraindicated to receive laser treatment; 4.Allergic to BTX treatment; 5.Past photosensitivity reaction; 6.Aged < 14 years; 7.Suffering from neuromuscular basic diseases such as myasthenia gravis; 8.Partial or systemic application of rosacea and other disease treatment drugs within 2 weeks; 9.Inability to follow up on schedule and other reasons cannot cooperate with the investigator.

Design outcomes

Primary

MeasureTime frame
Global Flushing Symptom Score;

Secondary

MeasureTime frame
pH;Visia Red Distinction Value;Sebum;Transepidermal water loss;Erythema index;Cuticle water content;

Countries

China

Contacts

Public ContactWa Qingbiao

Chengdu Second People's Hospital

295615394@qq.com+86 13981987190

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026